Page 44 - 《南京医科大学学报》2026年第1期
P. 44

第46卷第1期
              · 38   ·                           南 京    医 科 大 学 学         报                        2026年1月


                   Phase Ⅲ trial assessing bevacizumab in stages Ⅱ and Ⅲ  [39]GRAMLICH L,GUENTER P. Enteral nutrition in hospi⁃
                   carcinoma of the colon :results of NSABP protocol  talized adults[J]. N Engl J Med,2025,392(15):1518-
                   C⁃08[J]. J Clin Oncol,2011,29(1):11-16            1530
             [28]KAWAKAMI H,ZAANAN A,SINICROPE F A. Microsa⁃    [40]NOBELS A,VAN MARCKE C,JORDAN B F,et al. The
                   tellite instability testing and its role in the management of  gut microbiome and cancer:from tumorigenesis to thera⁃
                   colorectal cancer[J]. Curr Treat Options Oncol,2015,16  py[J]. Nat Metab,2025,7(5):895-917
                  (7):30                                        [41]KIM Y,KIM G,KIM S,et al. Fecal microbiota transplan⁃
             [29]CHALABI M,VERSCHOOR Y L,TAN P B,et al. Neoad⁃       tation improves anti⁃PD⁃1 inhibitor efficacy in unresec⁃
                   juvant immunotherapy in locally advanced mismatch re⁃  table or metastatic solid cancers refractory to anti⁃PD⁃ 1
                   pair⁃deficient colon cancer[J]. N Engl J Med,2024,390  inhibitor[J]. Cell Host Microbe,2024,32(8):1380-1393
                  (21):1949-1958                                [42]YU H,LI X X,HAN X,et al. Fecal microbiota transplan⁃
             [30]SINICROPE F A,OU F S,ARNOLD D,et al. Random⁃        tation inhibits colorectal cancer progression:reversing in⁃
                   ized trial of standard chemotherapy alone or combined  testinal microbial dysbiosis to enhance anti ⁃ cancer im⁃
                   with atezolizumab as adjuvant therapy for patients with  mune responses[J]. Front Microbiol,2023,14:1126808
                   stage Ⅲ deficient DNA mismatch repair(dMMR)colon  [43]REPETTO L,FRATINO L,AUDISIO R A,et al. Compre⁃
                   cancer(Alliance A021502;ATOMIC)[J]. J Clin Oncol,  hensive geriatric assessment adds information to Eastern
                   2025,43(17 suppl):CBA1                            cooperative oncology group performance status in elderly
             [31] WU X Y,SIA J V,HAI M,et al. Physiologically based  cancer patients:an italian group for geriatric oncology
                   pharmacokinetic model for older adults and its applica⁃  study[J]. J Clin Oncol,2002,20(2):494-502
                   tion in geriatric drug research[J]. Curr Drug Metab,  [44]梅  迪,韩惠秀,张  帅,等. 老年综合评估在中国老年
                   2023,24(3):211-222                                急性髓性白血病患者中的前瞻性研究[J]. 中华老年医
             [32]DARDEN D B,MOORE F A,BRAKENRIDGE S C,et al.         学杂志,2019,38(3):225-228
                   The effect of aging physiology on critical care[J]. Crit  MEI D,HAN H X,ZHANG S,et al. A prospective study
                   Care Clin,2021,37(1):135-150                      of comprehensive geriatric assessment in elderly patients
             [33]IBRAHIM K,COX N J,STEVENSON J M,et al. A sys⁃       with acute myeloid leukemia[J]. Chinese Joural of Geria⁃
                   tematic review of the evidence for deprescribing interven⁃  trics,2019,38(3):225-228
                   tions among older people living with frailty[J]. BMC Geri⁃  [45]BAI J F,HAN H X,FENG R,et al. Comprehensive geria⁃
                   atr,2021,21(1):258                                tric assessment(CGA):a simple tool for guiding the treat⁃
             [34]ZHU Y C,ZHANG Y T,HU X. Principles and measures     ment of older adults with diffuse large B⁃cell lymphoma in
                   of medication risk management in the elderly[J]. J Phar⁃  China[J]. Oncologist,2020,25(8):1202-1208
                   macovigilance,2023,20(9):1031-1034           [46]BROWDER T,BUTTERFIELD C E,KRÄLING B M,et
             [35]CAO F,WANG Y B,XUE W G,et al. Clinical multi⁃cen⁃   al. Antiangiogenic scheduling of chemotherapy improves
                   ters report of chronic diseases among elderly inpatients in  efficacy against experimental drug ⁃ resistant cancer[J].
                   China[J]. Chin J Mult Organ Dis Elderly,2018,17(11):  Cancer Res,2000,60(7):1878-1886
                   801-808                                      [47]SIMKENS L H J,VAN TINTEREN H,MAY A,et al.
                                                     ®
             [36]2023 American Geriatrics Society Beers Criteria Update  Maintenance treatment with capecitabine and bevacizumab
                   Expert Panel. American Geriatrics Society 2023 updated  in metastatic colorectal cancer(CAIRO3):a phase 3 ran⁃
                                ®
                   AGS Beers Criteria for potentially inappropriate medica⁃  domised controlled trial of the Dutch colorectal cancer
                   tion use in older adults[J]. J Am Geriatr Soc,2023,71  group[J]. Lancet,2015,385(9980):1843-1852
                  (7):2052-2081                                 [48]中国抗癌协会肿瘤临床化疗专业委员会. 肿瘤治疗相
             [37]LI W B,ZHANG Q. Research progress on coping strate⁃  关骨髓抑制院外管理专家共识(2025版)[J]. 中华医学
                   gies of unreasonable drug use in the elderly[J]. Chin J  杂志,2025,105(11):793-804
                   Geriatr,2023,42(2):239-242                        China Anti⁃cancer Association Tumor Clinical Chemothe⁃
             [38]PAPAMICHAEL D,RENFRO L A,MATTHAIOU C,et             rapy Professional Committee. Expert consensus on the out⁃
                   al. Validity of adjuvant! Online in older patients with  of ⁃ hospital management of myelosuppression associated
                   stage Ⅲ colon cancer based on 2 967 patients from the  with oncological treatment(2025 edition)[J]. Chinese
                   ACCENT database[J]. J Geriatr Oncol,2016,7(6):422-  Medical Journal,2025,105(11):793-804
                   429                                                                          (下转第46页)
   39   40   41   42   43   44   45   46   47   48   49